BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ruxolitinib (Opzelura) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ruxolitinib (Opzelura)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07049575-11030@assetmemo.bio
DTSTAMP:20261121T010012Z
DTSTART;VALUE=DATE:20261209
DTEND;VALUE=DATE:20261210
SUMMARY:Ruxolitinib (Opzelura): Phase 1 readout est. (NCT07049575)
DESCRIPTION:Ruxolitinib (Opzelura)\, phase 1\, Hidradenitis Suppurativa.\nS
 tudy: Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and 
 Adolescent Participants With Hidradenitis Suppurativa\nEstimated primary c
 ompletion: 9 December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ruxolitinib-opzelura#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07049575
URL:https://assetmemo.bio/drug/ruxolitinib-opzelura#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06804811-11030@assetmemo.bio
DTSTAMP:20261121T010012Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ruxolitinib (Opzelura): Phase 3 readout est. (NCT06804811)
DESCRIPTION:Ruxolitinib (Opzelura)\, phase 3\, Vitiligo.\nStudy: A Study to
  Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to <
  12 Years Old) With Nonsegmental Vitiligo\nEstimated primary completion: 3
 0 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolit
 inib-opzelura#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06804811
URL:https://assetmemo.bio/drug/ruxolitinib-opzelura#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07661979-11030@assetmemo.bio
DTSTAMP:20261121T010012Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Ruxolitinib (Opzelura): Phase 4 readout est. (NCT07661979)
DESCRIPTION:Ruxolitinib (Opzelura)\, phase 4\, Atopic Dermatitis.\nStudy: O
 pzelura Experience Study\nEstimated primary completion: August 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-opzelura#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07661979
URL:https://assetmemo.bio/drug/ruxolitinib-opzelura#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06548360-11030@assetmemo.bio
DTSTAMP:20261121T010012Z
DTSTART;VALUE=DATE:20280605
DTEND;VALUE=DATE:20280606
SUMMARY:Ruxolitinib (Opzelura): Phase 3 readout est. (NCT06548360)
DESCRIPTION:Ruxolitinib (Opzelura)\, phase 3\, Vitiligo.\nStudy: A Study to
  Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Partic
 ipants With Nonsegmental Vitiligo\nEstimated primary completion: 5 June 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-opzel
 ura#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06548360
URL:https://assetmemo.bio/drug/ruxolitinib-opzelura#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07595939-11030@assetmemo.bio
DTSTAMP:20261121T010012Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ruxolitinib (Opzelura): Phase 3 readout est. (NCT07595939)
DESCRIPTION:Ruxolitinib (Opzelura)\, phase 3\, Vitiligo.\nStudy: Efficacy a
 nd Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With No
 n-segmental Vitiligo\nEstimated primary completion: 31 December 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-opzelura#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07595939
URL:https://assetmemo.bio/drug/ruxolitinib-opzelura#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07783412-11030@assetmemo.bio
DTSTAMP:20261121T010012Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Ruxolitinib (Opzelura): Phase 2 readout est. (NCT07783412)
DESCRIPTION:Ruxolitinib (Opzelura)\, phase 2.\nStudy: Topical Ruxolitinib i
 n the Treatment of Adults With Pyoderma Gangrenosum\nEstimated primary com
 pletion: September 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ruxolitinib-opzelura#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07783412
URL:https://assetmemo.bio/drug/ruxolitinib-opzelura#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07801248-11030@assetmemo.bio
DTSTAMP:20261121T010012Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Ruxolitinib (Opzelura): Phase 1 readout est. (NCT07801248)
DESCRIPTION:Ruxolitinib (Opzelura)\, phase 1.\nStudy: Topical Ruxolitinib i
 n Acute Skin GVHD (Graft Versus Host Disease)\nEstimated primary completio
 n: October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxo
 litinib-opzelura#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07801248
URL:https://assetmemo.bio/drug/ruxolitinib-opzelura#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06857240-11030@assetmemo.bio
DTSTAMP:20261121T010012Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Ruxolitinib (Opzelura): Phase 2 readout est. (NCT06857240)
DESCRIPTION:Ruxolitinib (Opzelura)\, phase 2.\nStudy: Topical Ruxolitinib C
 ream for Refractory Cutaneous Dermatomyositis\nEstimated primary completio
 n: December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rux
 olitinib-opzelura#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06857240
URL:https://assetmemo.bio/drug/ruxolitinib-opzelura#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
